Organon price target raised to $20 from $19 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Organon (OGN) to $20 from $19 and keeps a Neutral rating on the shares. The firm cites the company’s announced FDA approval of VTAMA for the topical treatment of atopic dermatitis, or AD, in adults and pediatric patients 2 years of age and older. VTAMA’s AD approval addresses multiple unmet needs in the atopic dermatitis market previously demonstrated by their Phase 3 results, though the firm expects successful launch will require a heightened level of investment in sales/marketing support given the primary care dimensions of the AD market, the analyst tells investors in a research note.